Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
NCT02195869Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Jul 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Pharmacyclics. Started Jul 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02195869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195869.